Bariatric Surgery for ESRD Patients vs Control

Obesity Clinical Trial

Official title:

Obesity, End-Stage Renal Disease and Kidney Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00580762
• Other study ID #: 0508000519
• Status: Terminated
• Phase: N/A
• First received: December 18, 2007
• Last updated: September 2, 2016
• Start date: October 2005
• Est. completion date: July 2011

Study information

• Verified date: September 2016
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study will address a true clinical problem by developing a risk/benefit analysis for rapid surgical weight loss in the ESRD population. The risks of surgical intervention, as well as, potential nutritional concerns, balanced with that of the potential medical benefits associated with significant weight loss.

Description:

The study will be designed to compare two cohorts of patients that will undergo laparoscopic RYGB. Cohort 1 will include ESRD patients on HD who meet the NIH guidelines and preoperative requirements for RYGB. Cohort 2 will include non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB. Laparoscopic RYGB will be performed in ESRD patients who meet the guidelines recommended by the National Institutes of Health consensus statement . This includes patients who either have a BMI≥40 kg/m2 or have a BMI≥35 kg/m2 and have a significant morbidity attributed to their obesity (i.e. sleep apnea, hypertension, and diabetes mellitus). All patients will undergo a complete pre-operative evaluation inclusive of dietary instruction, assessment of surgical risk, psychosocial evaluation and compliance evaluation. This evaluation will be conducted through an existing infrastructure at the investigators Bariatric Surgery Center. Patients will be required to be on hemodialysis or able to be converted to hemodialysis for the perioperative period. All procedures will be performed by the same team of surgeons, experienced in both laparoscopic RYGB, organ transplantation and general surgery in ESRD patients. The risks involved with Roux-en-Y gastric bypass surgery will be discussed with the patient. These risks are inherent to the procedure, however the procedure is being conducted for medical appropriate reasons and therefore the benefits to the procedure outweigh the risks. At the present time, it is believed, without any justification, that this procedure is more risky or too risky in the ESRD population. A primary objective of this study is to investigate this question.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: July 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Obese ESRD patients with a BMI= 40kg/m2 or =35kg/m2 with an medical complication attributed to morbid obesity (NIH guidelines).REF

2. Age = 18 and = 65

3. Patients must be on hemodialysis for one month.

4. Patients listed for kidney transplant in a UNOS certified kidney transplant center.

5. Patients have accrued less than 18 months of waiting time.

6. Completion of pre-RYGB psychosocial evaluation.

7. Completion of pre-RYGB dietary counseling.

8. Completion of pre-RYGB surgical risk assessment inclusive of cardiac evaluation.

9. Full reciprocal understanding of informed consent and the risks and benefits of RYGB procedure.

10. Acceptance of clinical protocol evaluations requiring scheduled clinic visits and laboratory blood draws.

Exclusion Criteria:

1. Age < 18 and > 65.

2. Patients with a history of peritoneal dialysis related bacterial peritonitis.

3. Peritoneal dialysis patients not willing to undergoing temporary hemodialysis.

4. History of difficult vascular access as defined by the inability to obtain permanent upper extremity or temporary jugular venous access.

5. History of poor hemodialysis performance.

6. Patients enrolled in another study within 6 months of initiation.

7. Patients listed for kidney transplant in a different UNOS region that has shorter transplant waiting times than the region governing the investigators institution.

8. Patients unwilling to be made temporarily unavailable for transplant.

9. History of non-compliance with medical care.

10. Uncontrolled psychiatric illness (ie. depression, anxiety, attention deficit disorder (ADD), uncontrolled binge eating disorder)

11. Inability to provide reciprocal understanding of informed consent.

12. Failure to complete the preoperative work-up (psychosocial, dietary and surgical risk) for RYGB.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• ESRD
• Obesity

Intervention

Procedure:
• Roux-en-y gastric bypass (RYGB)

Locations

Country	Name	City	State
United States	Yale University School of Medicine	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The safety and efficacy of laparoscopic RYGB in obese ESRD patients will be assessed.		1 year	Yes
Secondary	Weight reduction in ESRD patients will be characterized to assess additive risk factors for micronutrient abnormalities and protein malnutrition.		1 year	Yes